tbuckley/cabot-search huggingface dataset:
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Authors: Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howng, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, Martin Pool
Journal: Clinical Cancer Research (2020)

Probody therapeutic CX-072 is a protease-activatable antibody that is cross-reactive with murine and human programmed death-ligand 1 (PD-L1). CX-072 can be activated in vivo by proteases present in the tumor microenvironment, thereby potentially reducing peripheral, anti-PD-L1-mediated toxicities. To study its targeting of PD-L1-expressing tissues, we radiolabeled CX-072 with the PET isotope zirconium-89 (89Zr).89Zr-labeled CX-072, nonspecific Probody control molecule (PbCtrl) and CX-072 parental antibody (CX-075) were injected in BALB/c nude mice bearing human MDA-MB-231 tumors or C57BL/6J mice bearing syngeneic MC38 tumors. Mice underwent serial PET imaging 1, 3, and 6 days after intravenous injection (pi), followed by ex vivo biodistribution. Intratumoral 89Zr-CX-072 distribution was studied by autoradiography on tumor tissue sections, which were subsequently stained for PD-L1 by IHC. Activated CX-072 species in tissue lysates were detected by Western capillary electrophoresis.PET imaging revealed 89Zr-CX-072 accumulation in MDA-MB-231 tumors with 2.1-fold higher tumor-to-blood ratios at 6 days pi compared with 89Zr-PbCtrl. Tumor tissue autoradiography showed high 89Zr-CX-072 uptake in high PD-L1-expressing regions. Activated CX-072 species were detected in these tumors, with 5.3-fold lower levels found in the spleen. Furthermore, 89Zr-CX-072 uptake by lymphoid tissues of immune-competent mice bearing MC38 tumors was low compared with 89Zr-CX-075, which lacks the Probody design.89Zr-CX-072 accumulates specifically in PD-L1-expressing tumors with limited uptake in murine peripheral lymphoid tissues. Our data may enable clinical evaluation of 89Zr-CX-072 whole-body distribution as a tool to support CX-072 drug development (NCT03013491).
P-0161 Evaluation of Doses to Organs at Risk in Conformal Radiotherapy of Periampullary Cancers: Implications for Dose Escalation by IMRT
Authors: Amit Bahhl, R. Kapoor, O. Singh, Parsee Tomar, Arvind Shukla, Tapesh Bhattacharyya, Pramod Singh, None Sharmas
Journal: Annals of Oncology (2012)
Gefapixant in two randomised dose-escalation studies in chronic cough
Authors: Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
Journal: European Respiratory Journal (2020)

Background and objectives Gefapixant has previously demonstrated efficacy in the treatment of refractory chronic cough at a high daily dose. The current investigations explore efficacy and tolerability of gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough using a dose-escalation approach. Materials and methods Two randomised, double-blind, placebo-controlled, crossover, dose-escalation studies recruited participants with refractory chronic cough. Patients were assigned to receive ascending doses of gefapixant (study 1: 50–200 mg, study 2: 7.5–50 mg) or placebo for 16 days, then crossed-over after washout. The primary end-point was awake cough frequency assessed using a 24-h ambulatory cough monitor at baseline and on day 4 of each dose. Patient-reported outcomes included a cough severity visual analogue scale and the cough severity diary. Results In clinical studies, gefapixant doses ≥30 mg produced maximal improvements in cough frequency compared with placebo (p&lt;0.05); reported cough severity measures improved at similar doses. Taste disturbance exhibited a different relationship with dose, apparently maximal at doses ≥150 mg. Conclusions P2X3 antagonism with gefapixant demonstrates anti-tussive efficacy and improved tolerability at lower doses than previously investigated. Studies of longer duration are warranted.
Orai1 Channel Inhibition Preserves Left Ventricular Systolic Function and Normal Ca <sup>2+</sup> Handling After Pressure Overload
Authors: Fiona Bartoli, Marc A. Bailey, Baptiste Rode, Philippe Mateo, Fabrice Antigny, Kaveen Bedouet, Pascale Gerbaud, Rajendra Gosain, Jeffrey Plante, Katherine Norman, Susana Gomez, Florence Lefebvre, Catherine Rucker-Martin, Justin F.X. Ainscough, Mark T. Kearney, Alexander-Francisco Bruns, Jian Shi, Hollie L. Appleby, Richard S. Young, Heba M. Shawer, Marjolaine Debant, Ana-Maria Gomez, David J. Beech, Richard Foster, Jean-Pierre Benitah, Jessica Sabourin
Journal: Circulation (2020)

Background: Orai1 is a critical ion channel subunit, best recognized as a mediator of store-operated Ca 2+ entry (SOCE) in nonexcitable cells. SOCE has recently emerged as a key contributor of cardiac hypertrophy and heart failure but the relevance of Orai1 is still unclear. Methods: To test the role of these Orai1 channels in the cardiac pathophysiology, a transgenic mouse was generated with cardiomyocyte-specific expression of an ion pore-disruptive Orai1 R91W mutant (C-dnO1). Synthetic chemistry and channel screening strategies were used to develop 4-(2,5-dimethoxyphenyl)-N-[(pyridin-4-yl)methyl]aniline (hereafter referred to as JPIII), a small-molecule Orai1 channel inhibitor suitable for in vivo delivery. Results: Adult mice subjected to transverse aortic constriction (TAC) developed cardiac hypertrophy and reduced ventricular function associated with increased Orai1 expression and Orai1-dependent SOCE (assessed by Mn 2+ influx). C-dnO1 mice displayed normal cardiac electromechanical function and cellular excitation-contraction coupling despite reduced Orai1-dependent SOCE. Five weeks after TAC, C-dnO1 mice were protected from systolic dysfunction (assessed by preserved left ventricular fractional shortening and ejection fraction) even if increased cardiac mass and prohypertrophic markers induction were observed. This is correlated with a protection from TAC-induced cellular Ca 2+ signaling alterations (increased SOCE, decreased [Ca 2+ ] i transients amplitude and decay rate, lower SR Ca 2+ load and depressed cellular contractility) and SERCA2a downregulation in ventricular cardiomyocytes from C-dnO1 mice, associated with blunted Pyk2 signaling. There was also less fibrosis in heart sections from C-dnO1 mice after TAC. Moreover, 3 weeks treatment with JPIII following 5 weeks of TAC confirmed the translational relevance of an Orai1 inhibition strategy during hypertrophic insult. Conclusions: The findings suggest a key role of cardiac Orai1 channels and the potential for Orai1 channel inhibitors as inotropic therapies for maintaining contractility reserve after hypertrophic stress.
Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.
Authors: Ofer Purim, Alina Weismann-Brenner, Michal Kushnir, Gila Lithwick-Yanai, Ranit T. Aharonov, Hadas Gibori, Yulia Kundel, Sara Morgenstern, Marisa Halpern, Yaron Niv, Baruch Brenner
Journal: Journal of Clinical Oncology (2012)

e14067 Background: To compare the microRNA (miRNA) profiles in the primary tumor of patients with recurrent and non-recurrent colon cancer. Methods: The study population included 110 patients, 51 (46%) with stage I and 59 (54%) with stage II disease, who underwent curative colectomies between 1995-2005 without adjuvant therapy and for whom reliable miR expression data was available. RNA was extracted from formalin-fixed paraffin-embedded tumor samples. Initial profiling, using microarrays, was done in order to identify potential biomarkers of recurrence. The miRNA expression was later verified by quantitative real-time polymerase chain reaction (qRT-PCR). Findings were compared between patients who had a recurrence within 36 months of surgery (bad prognosis group, n=23, 21%) and those who did not (good prognosis group, n=87, 79%) in the entire group and within each stage. Results: In stage I, none of the 903 miRNAs tested showed differential expression between patients with good prognosis compared with those with bad prognosis. In stage II, one miRNA, miR-29a, showed a clear differential expression between the groups (p=0.028). High expression of miR-29a was associated with a longer disease-free survival (DFS), on both univariate and multivariate analyses. Using miR-29a, the positive predictive value for non-recurrence was 94% (2 recurrences among 31 patients). The differential expression of miR-29a was verified by qRT-PCR, showing a similar impact of this miR on DFS. Conclusions: This study demonstrated a significant impact of miR-29a on the risk of recurrence in patients with stage II but not in patients with stage I colon cancer.
Reply to the Letter to the Editor: “Mixing Apples and Oranges in Assessing Outcomes of Repetitive Transcranial Stimulation Meta-Analyses”
Authors: Ali Amad, Renaud Jardri, Chloé Rousseau, Yann Larochelle, John P.A. Ioannidis, Florian Naudet
Journal: Psychotherapy and Psychosomatics (2020)
Can Time from Last Chemotherapy to Recurrence be a Predictor of Chemosensitivity in Rcurrent Globlastoma?
Authors: E. Franceschi, R. Agati, R. Poggi, P. Dall'Occa, M. Bartolotti, M. Di Battista, G. Marucci, F. Girardi, M. Ermani, A. Brandes
Journal: Annals of Oncology (2012)
Human umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization
Authors: Shareen Forbes, Andrew R. Bond, Kayleigh L. Thirlwell, Paul Burgoyne, Kay Samuel, June Noble, Gary Borthwick, David Colligan, Neil W. A. McGowan, Philip Starkey Lewis, Alasdair R. Fraser, Joanne C. Mountford, Roderick N. Carter, Nicholas M. Morton, Marc L. Turner, Gerard J. Graham, John D. M. Campbell
Journal: Science Translational Medicine (2020)

Islet transplantation is an efficacious therapy for type 1 diabetes; however, islets from multiple donor pancreata are required, and a gradual attrition in transplant function is seen. Here, we manufactured human umbilical cord perivascular mesenchymal stromal cells (HUCPVCs) to Good Manufacturing Practice (GMP) standards. HUCPVCs showed a stable phenotype while undergoing rapid ex vivo expansion at passage 2 (p2) to passage 4 (p4) and produced proregenerative factors, strongly suppressing T cell responses in the resting state and in response to inflammation. Transplanting an islet equivalent (IEQ):HUCPVC ratio of 1:30 under the kidney capsule in diabetic NSG mice demonstrated the fastest return to normoglycemia by 3 days after transplant: Superior glycemic control was seen at both early (2.7 weeks) and later stages (7, 12, and 16 weeks) versus ratios of 1:0, 1:10, and 1:50, respectively. Syngeneic islet transplantation in immunocompetent mice using the clinically relevant hepatic portal route with a marginal islet mass showed that mice transplanted with an IEQ:HUCPVC ratio of 1:150 had superior glycemic control versus ratios of 1:0, 1:90, and 1:210 up to 6 weeks after transplant. Immunodeficient mice transplanted with human islets (IEQ:HUCPVC ratio of 1:150) exhibited better glycemic control for 7 weeks after transplant versus islet transplant alone, and islets transplanted via the hepatic portal vein in an allogeneic mouse model using a curative islet mass demonstrated delayed rejection of islets when cotransplanted with HUCPVCs (IEQ:HUCPVC ratio of 1:150). The immunosuppressive and proregenerative properties of HUCPVCs demonstrated long-term positive effects on graft function in vivo, indicating that they may improve long-term human islet allotransplantation outcomes.
Phase I/II Dose-Finding Study of Crizotinib (CRIZ) in Combination with Erlotinib (E) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: S.I. Ou, R. Govindan, K. Eaton, A. Argiris, G. Otterson, F. Robert, N. Brega, T. Usari, W. Tan, M. Gutierrez
Journal: Annals of Oncology (2012)
From surface to bulk modification: Plasma polymerization of amine-bearing coating by synergic strategy of biomolecule grafting and nitric oxide loading
Authors: Tong Yang, Zeyu Du, Hua Qiu, Peng Gao, Xin Zhao, Huaiyu Wang, Qiufen Tu, Kaiqin Xiong, Nan Huang, Zhilu Yang
Journal: Bioactive Materials (2020)

Integration of two or more biomolecules with synergetic and complementary effects on a material surface can help to obtain multi-functions for various biomedical applications. However, the amounts of biomolecules integrated and their physiological functions are compromised due to the limited surface anchoring sites. Herein, we propose a novel concept of film engineering strategy "from surface to bulk synergetic modification". This new concept is realized by employing the surface amine groups of plasma polymerized allylamine (PPAm) film for grafting a molecule e.g., thrombin inhibitor, bivalirudin (BVLD), meanwhile its bulk amine groups is used as a universal depot for storing and releasing therapeutic nitric oxide (NO) gas as supplement to the functions of BVLD. It is demonstrated that such a "from surface to bulk synergetic modification" film engineering can impart the modified-substrates with anti-platelet and anti-coagulant dual functions, giving rise to a highly endothelium-mimetic thromboresistant property. We believe that our research provides a very promising strategy to deliver multifunctional surface versatilely that require NO release in combination with other properties, which will find broad biomedical applications in blood-contacting devices, and et al. Moreover, it also provides a brand-new film engineering strategy for tailoring surface multi-functionalities of a wide range of materials.
High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity
Authors: Tom Erkers, Bryan J. Xie, Laura J. Kenyon, Brian Smith, Mary Rieck, Kent P. Jensen, Xuhuai Ji, Marina Basina, Samuel Strober, Robert S. Negrin, Holden T. Maecker, Everett H. Meyer
Journal: Blood (2020)
Size matters! Peripheral blood leukocyte telomere length and survival after critical illness
Authors: Florian B. Mayr, Sachin Yende
Journal: European Respiratory Journal (2020)

In 2009, Elizabeth Blackburn, Jack Szostak and Carol Greider were awarded the Nobel Prize in Physiology or Medicine for their pioneering work that led to the discovery of telomeres and the enzyme complex telomerase responsible for maintaining its structure [1]. Over the past four decades, the classic view of telomeres protecting the natural ends of linear chromosomes and telomerase as telomere-terminal transferase necessary for the replication of chromosome ends has significantly evolved. Many diverse fields have matured, including the discovery of key molecular components of telomerase, implications for limits to cellular replication, and identification and characterisation of human genetic disorders that result in premature telomere shortening [2]. The association of shorter leukocyte telomere length and reduced survival in critical illness may prove crucial in our quest to improve outcomes <http://bit.ly/2qDAZSq>
Feasibility and Usefulness of Determining EGFR and KRAS Mutations in Cytological Samples and CNB of NSCLC Using an Automated Real-Time PCR System
Authors: M.D. Lozano, T. Labiano, M. Montañana, J.I. Echeveste, A. Gurpide, J.L. Pérez Gracia, F. Shieh, T. Ramos, J. Zulueta, S. Martin Algarra
Journal: Annals of Oncology (2012)
The study of Lynch syndrome in a special population reveals a strong founder effect and an unusual mutational mechanism in familial adenomatous polyposis
Authors: Abdul K Siraj, Tariq Masoodi, Rong Bu, Sandeep Kumar Parvathareddy, Sarah Siraj, Ali Alassiri, Fouad Al-Dayel, Fowzan S Alkuraya, Khawla S Al-Kuraya
Journal: Gut (2020)

We read with interest the study by Moller and colleagues.1 The isolation and relative homogeneity of the Saudi population enhance the potential to discover founder mutations, while its high rates of consanguinity enhances homozygosity even for typically dominant disease genes.2 3 We have previously explored the contribution of Lynch syndrome (LS) to colorectal cancer (CRC) based on ~800 Saudi patients.4 We have since expanded our cohort to 1207 CRC patients. Of the 112 mismatch repair deficient (dMMR) cases, MMR gene mutations were identified in 26 cases and these varied in their cancer risk by age 50 years (figure 1). Three founder mutations were observed, accounting for 42.3% (n=11) of LS cases, and none is listed in gnomAD. The PMS2 :c.1376C>G;p.S459X variant was the most commonly encountered LS variant (n=6), and we calculated its minor allele frequency at 0.0001. ​ Importantly, we were able to identify a homozygous individual for PMS2 :c.1376C>G;p.S459X through a large scale whole-exome sequencing (WES) study.2 This individual presented at age 8 years with haematochezia and a typical picture of familial adenomatous …
アシアロエリスロポエチンは,心不全の病因にかかわらず広範な抗心不全活性を示す | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Takeyama Toshiaki, Takemura Genzo, Kanamori Hiromitsu, Ogino Atsushi, Kawaguchi Tomonori, Watanabe Takatomo, Morishita Kentaro, Tsujimoto Akiko, Goto Kazuko, Fujiwara Takako, Fujiwara Hisayoshi, Minatoguchi Shinya
Journal: Circulation (2012)
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
Authors: Robert  A. McCutcheon, John H. Krystal, Oliver D. Howes
Journal: World Psychiatry (2020)

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both have been proposed to contribute significantly to the pathophysiology of schizophrenia. In this paper we assess research that has implicated both systems in the aetiology of this disorder. We examine evidence from post‐mortem, preclinical, pharmacological and in vivo neuroimaging studies. Pharmacological and preclinical studies implicate both systems, and in vivo imaging of the dopamine system has consistently identified elevated striatal dopamine synthesis and release capacity in schizophrenia. Imaging of the glutamate system and other aspects of research on the dopamine system have produced less consistent findings, potentially due to methodological limitations and the heterogeneity of the disorder. Converging evidence indicates that genetic and environmental risk factors for schizophrenia underlie disruption of glutamatergic and dopaminergic function. However, while genetic influences may directly underlie glutamatergic dysfunction, few genetic risk variants directly implicate the dopamine system, indicating that aberrant dopamine signalling is likely to be predominantly due to other factors. We discuss the neural circuits through which the two systems interact, and how their disruption may cause psychotic symptoms. We also discuss mechanisms through which existing treatments operate, and how recent research has highlighted opportunities for the development of novel pharmacological therapies. Finally, we consider outstanding questions for the field, including what remains unknown regarding the nature of glutamate and dopamine function in schizophrenia, and what needs to be achieved to make progress in developing new treatments.
Lower Bacillus Calmette-Guérin Protection against <i>Mycobacterium tuberculosis</i> Infection after Exposure to Beijing Strains
Authors: Ayesha J. Verrall, Lidya Chaidir, Carolien Ruesen, Lika Apriani, Raspati C. Koesoemadinata, Jakko van Ingen, Katrina Sharples, Reinout van Crevel, Bachti Alisjahbana, Philip C. Hill, Ayesha J. Verrall, Lidya Chaidir, Carolien Ruesen, Lika Apriani, James E. Ussher, Arjan van Laarhoven, Raspati C. Koesoemadinata, Dwi F. Ratnaningsih, Rovina Ruslami, Martijn Huynen, Mihai G. Netea, Jakko van Ingen, Katrina Sharples, Reinout van Crevel, Bachti Alisjahbana, Philip C. Hill
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
A Phase 2 Randomized Trial of Docetaxel Alone or in Combination with Therapeutic Cancer Vaccine, CEA-, MUC-1-Tricom
Authors: C. Heery, N. Ibrahim, R.A. Madan, M. Mohebtash, P. Arlen, S. McMahon, S. Hodge, S.M. Steinberg, J. Schlom, J.L. Gulley
Journal: Annals of Oncology (2012)
Efficacy and Safety of Everolimus in Postmenopausal Women With Advanced Breast Cancer (BOLERO-2): Effect of Visceral Metastases and Prior Endocrine Therapy
Authors: M. Campone, S. Noguchi, K. Pritchard, H. Rugo, G.N. Hortobagyi, J. Baselga, A. Panneerselvam, T. Taran, T. Sahmoud, M. Piccart
Journal: Annals of Oncology (2012)
A pigmented lesion on the eye
Authors: Olivia M Bennett, Rajesh C Rao
Journal: BMJ (2020)

A 46 year old white woman was referred for ophthalmologic evaluation of a pigmented lesion on the ocular surface of her left eye. The lesion had been noted during a routine eye examination by her general practitioner. She had first noticed the lesion six years earlier, believing it to be gradually increasing in size. Slit lamp biomicroscopy of the eye is shown in fig 1. No cysts were noted within the lesion and no other lesions were evident on complete ophthalmic examination, which included eversion of the eyelids and …
Problems With Clinical Application of Low-Dose Vasopressin for Traumatic Hemorrhagic Shock
Authors: Makoto Aoki, Toshikazu Abe, Kiyohiro Oshima
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Prognostic Significance of Combined Positivity of Lymphatic, Vascular, and Perineural Invasion (TRIPLE POSITIVE) in Stage II/III Colorectal Cancer; A New Paradigm Worth to Investigate?
Authors: F. Dane, M.A. Ozturk, M. Koçar, B.M. Atasoy, B. Aktas, F. Telli, M. Kanıtez, M. Bes¸irog˘lu, P.F. Yumuk, S.N. Turhal
Journal: Annals of Oncology (2012)
Overdose Reversals Save Lives–Period
Authors: Nathaniel P. Morris, Robert A. Kleinman
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Activity and Safety of a Combination of Epirubicin, Docetaxel and Cisplatin as Neoadjuvant Treatment for Locally Advanced Breast Cancer (LABC): A Preliminary Report
Authors: N. Avci, O. Kanat, S. Gokgoz, S. Tolunay, U. Topal, E. Cubukcu, F. Olmez
Journal: Annals of Oncology (2012)